, Tracking Stock Market Picks
Enter Symbol:

up 129.59 %

ARDEA BIOSCIENCES (RDEA) rated Buy by Merriman Curhan Ford

Posted on: Thursday,  Jan 8, 2009  8:25 AM ET by Merriman Curhan Ford

Merriman Curhan Ford rated Buy ARDEA BIOSCIENCES (NASDAQ: RDEA) on 01/08/2009, when the stock price was $13.92. Since
then, ARDEA BIOSCIENCES has gained 129.60% as of 06/19/2012's recent price of $31.96.
If you would have followed this Merriman Curhan Ford's recommendation on RDEA, you would have gained 129.59% of your investment in 1258 days.

Ardea Biosciences, Inc. is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of human immunodeficiency virus (HIV), cancer and inflammatory diseases, including gout. The Company's portfolio of product candidates include RDEA806 and 2nd generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV indication; RDEA594 for gout; RDEA119 for cancer; RDEA119 for inflammation, and mitogen-activated ERK kinase (MEK) inhibitor for cancer/inflammation.

We occupy a unique niche among our investment banking peers: we offer our clients both traditional sell-side equity research and primary market research, and we focus on high-potential sectors such as CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. Our institutional and corporate clients get the best of both worlds: expertise from our analysts and access to experts through our Panel Intelligence platform.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/8/2009 8:25 AM Buy
as of 12/31/2009
1 Week up  76.16 %
1 Month up  91.60 %
3 Months up  40.77 %
1 YTD up  85.27 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy